Industry Dialogue on PRIP Strengthens Pharma Ecosystem
17 Mar 2025
3 Min Read
CW Team
The Department of Pharmaceuticals, Government of India, convened an Industry Dialogue in Mumbai to discuss the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme. The event brought together industry leaders, research institutions, and pharmaceutical associations, including representatives from the Indian Council for Medical Research (ICMR), the Council of Scientific and Industrial Research (CSIR), and the National Institute of Pharmaceutical Education and Research (NIPERs). Discussions focused on strengthening industry-academia linkages, fostering collaboration, and leveraging government initiatives to accelerate R&D and commercialise innovative solutions in the pharmaceutical and medical technology sectors.
Government Initiatives to Boost Innovation
In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector:
ICMR鈥檚 PATENT MITRA, MEDTECH MITRA, and INTENT programs 鈥� Supporting patent filing, guiding the innovation journey, and facilitating clinical trials.
CSIR鈥檚 Innovation Complex in Mumbai 鈥� Bridging the gap between research institutions and industry through translational research.
Industry Leaders Call for Stronger Policy and Investment Support
Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D:
Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) 鈥� Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies.
Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) 鈥� Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D.
Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) 鈥� Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme鈥檚 role in catalysing innovation.
Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) 鈥� Spoke on India鈥檚 potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions.
Government鈥檚 Vision for Future-Ready Healthcare Solutions
Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India鈥檚 global leadership in pharmaceuticals and MedTech. He emphasised that:
Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D.
India, with its highly diverse gene pool and one-sixth of the world鈥檚 population, has a unique advantage in developing personalised and precision medicines.
The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems.
Breakout Sessions and Stakeholder Engagement
The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered:
Enhancing industry-academia collaboration to drive research and innovation.
Streamlining regulatory pathways to facilitate faster commercialisation of new technologies.
Scaling up research initiatives to fuel sectoral growth.
Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme鈥檚 implementation to better align with industry needs.
The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.
The Department of Pharmaceuticals, Government of India, convened an Industry Dialogue in Mumbai to discuss the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme. The event brought together industry leaders, research institutions, and pharmaceutical associations, including representatives from the Indian Council for Medical Research (ICMR), the Council of Scientific and Industrial Research (CSIR), and the National Institute of Pharmaceutical Education and Research (NIPERs). Discussions focused on strengthening industry-academia linkages, fostering collaboration, and leveraging government initiatives to accelerate R&D and commercialise innovative solutions in the pharmaceutical and medical technology sectors.
Government Initiatives to Boost Innovation
In addition to the PRIP Scheme, the dialogue highlighted key government initiatives aimed at promoting research and innovation in the sector:
ICMR鈥檚 PATENT MITRA, MEDTECH MITRA, and INTENT programs 鈥� Supporting patent filing, guiding the innovation journey, and facilitating clinical trials.
CSIR鈥檚 Innovation Complex in Mumbai 鈥� Bridging the gap between research institutions and industry through translational research.
Industry Leaders Call for Stronger Policy and Investment Support
Prominent industry figures voiced their insights on the challenges and opportunities in Pharma-MedTech R&D:
Dr Sharvil Patel, Vice President, Indian Pharmaceutical Association (IPA) 鈥� Stressed the importance of industry-driven innovation, regulatory support, and increased investments in emerging pharmaceutical technologies.
Mr Anil Matai, Director General, Organisation of Pharmaceutical Producers of India (OPPI) 鈥� Highlighted the need for a conducive policy environment to encourage greater industry participation in R&D.
Mr Bharat Shah, National President, Indian Drug Manufacturers' Association (IDMA) 鈥� Addressed the challenges MSMEs face in adopting research-led growth strategies and welcomed the PRIP scheme鈥檚 role in catalysing innovation.
Mr Veeraal Gandhi, Vice President, Association of Diagnostics Manufacturers India (ADMI) 鈥� Spoke on India鈥檚 potential to lead in diagnostic technologies, particularly in point-of-care innovations, to enhance advanced healthcare solutions.
Government鈥檚 Vision for Future-Ready Healthcare Solutions
Shri Amit Agrawal, Secretary, Department of Pharmaceuticals, underscored the importance of futuristic products and affordable healthcare solutions as key drivers of India鈥檚 global leadership in pharmaceuticals and MedTech. He emphasised that:
Data-driven markets will play a transformative role in shaping Pharma-MedTech R&D.
India, with its highly diverse gene pool and one-sixth of the world鈥檚 population, has a unique advantage in developing personalised and precision medicines.
The PRIP Scheme aims to support innovative, cost-effective, and affordable healthcare solutions that will strengthen domestic and global healthcare ecosystems.
Breakout Sessions and Stakeholder Engagement
The event featured breakout sessions, where industry representatives and stakeholders provided insights on emerging R&D trends, regulatory pathways, and funding opportunities. Discussions covered:
Enhancing industry-academia collaboration to drive research and innovation.
Streamlining regulatory pathways to facilitate faster commercialisation of new technologies.
Scaling up research initiatives to fuel sectoral growth.
Stakeholders were encouraged to submit their feedback and project details via the Expression of Interest (EoI) on the Department of Pharmaceuticals website, open until April 7, 2025. This process aims to refine the PRIP Scheme鈥檚 implementation to better align with industry needs.
The Industry Dialogue in Mumbai concluded on a highly optimistic note, with participants reaffirming their commitment to fostering an innovation-driven ecosystem in the Pharma-MedTech sector. The event reinforced government-industry collaboration, paving the way for transformative advancements in healthcare, pharmaceuticals, and medical technology.
Next Story
3i Infotech Reports Rs 7.25 Bn Revenue for FY25
3i Infotech, a leading provider of digital transformation, technology services and technology solutions, announced its consolidated financial results for the fourth quarter and full year FY25, ended on March 31st, 2025. The company maintained its growth momentum, displaying consistent progress for the 3rd consecutive quarter.In Q4 FY25, 3i Infotech reported revenue of Rs 1.87 billion, reflecting steady performance compared to Rs 1.81 billion in Q3 FY25 and Rs 1.97 billion in Q4 FY24. The company delivered strong profitability improvements, with gross margin growing by 14.8 per cent Q-o-Q and 1..
Next Story
Emerald Finance Joins Baya PTE to Boost SME Bill Discounting
Emerald Finance is a dynamic company offering a spectrum of financial products and services including its flagship Earned Wage Access (EWA) in India, has entered into a strategic partnership with Singapore-based Baya PTE through its Indian subsidiary. This collaboration aims to strengthen bill discounting services for Small and Medium Enterprises (SMEs), enabling faster access to working capital and improved cash flow management.The initiative is designed to support SMEs that supply to large corporates such as JSW Steel, Delhivery, and PVR INOX, among others. By facilitating timely invoice dis..
Next Story
BLS E-Services Crosses Rs 5 Bn Revenue Mark in FY25
BLS E-Services, a technology-enabled digital service provider, announced its audited consolidated financial results for the quarter and full year period ended 31 March 2025.Speaking about the performance and recent updates, Shikhar Aggarwal, Chairman, BLS E- Services said, 鈥淲e are delighted to report a remarkable performance in FY25, as we achieved several milestones during the fiscal year. FY25 marked our highest-ever financial performance, as we surpassed Rs 5 billion milestone in Total Income during the year, which was reported at Rs 5.45 billion, a notable YoY growth of 76 per cent. The ..
